|
126 Companies |
|
141 Products |
|
141 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1237 News |
|
| «12345678910111213...2425» |
- | Pozenveo (poziotinib) / Assertio
Trial completion, Trial primary completion date, Metastases: A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer (clinicaltrials.gov) - Mar 4, 2016
P1/2, N=44, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2015
- || Herceptin (trastuzumab) / Roche
Enrollment change, Trial primary completion date: EVIDENCE: A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=1600, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2015 N=2600 --> 1600 | Trial primary completion date: Jun 2018 --> Dec 2017
- rilotumumab (AMG 102) / Amgen
Trial primary completion date, Metastases: Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ (clinicaltrials.gov) - Feb 29, 2016
P1, N=21, Completed, Sponsor: Amgen
N=2600 --> 1600 | Trial primary completion date: Jun 2018 --> Dec 2017 Trial primary completion date: Apr 2014 --> Aug 2013
- ||||||| pantoprazole / Generic mfg.
Trial completion: Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage (clinicaltrials.gov) - Feb 27, 2016
P3, N=149, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Trial primary completion date: Apr 2014 --> Aug 2013 No longer recruiting --> Completed
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion, Surgery: Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery (clinicaltrials.gov) - Feb 27, 2016
P3, N=60, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Active, not recruiting --> Completed
- cisplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Trial termination: Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=30, Terminated, Sponsor: Centre Hospitalier Universitaire de Besancon
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Feb 12, 2016
P1/2, N=44, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Terminated Trial primary completion date: Apr 2016 --> Apr 2017
- Trial primary completion date, BRCA Biomarker: Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=1905, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- Trial completion: Pain After Endoscopic Submucosal Dissection (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=156, Completed, Sponsor: Gangnam Severance Hospital
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Completed
- Trial completion, Metastases: FLOT3: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (clinicaltrials.gov) - Feb 3, 2016
P2, N=252, Completed, Sponsor: Krankenhaus Nordwest
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Surgery, Compliance: Compliance to ERAS After Gastric Surgery (clinicaltrials.gov) - Feb 2, 2016
P2, N=168, Completed, Sponsor: Chonnam National University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Jan 30, 2016
P1/2, N=53, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2016
- Trial completion: KSWEET-01: No Antimicrobial Prophylaxis for Laparoscopic Distal Gastrectomy (clinicaltrials.gov) - Jan 28, 2016
P2, N=98, Completed, Sponsor: Korean South West East Gastric Surgery Group
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Completed
- epinephrine / Generic mfg.
Trial completion, Trial primary completion date: Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps for Acute Peptic Ulcer Bleeding (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=151, Completed, Sponsor: Kyunghee University Medical Center
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Jun 2014
- Trial primary completion date: Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis (clinicaltrials.gov) - Jan 17, 2016
P2, N=50, Recruiting, Sponsor: G
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Jun 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- netazepide (YF476) / Trio Medicines
Trial primary completion date: YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome (clinicaltrials.gov) - Jan 17, 2016
P2, N=30, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Folotyn (pralatrexate) / Aurobindo
Trial completion, Combination therapy, Metastases: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 16, 2016
P2, N=35, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2015 --> Dec 2017 Active, not recruiting --> Completed
- Xpovio (selinexor) / Karyopharm
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus (clinicaltrials.gov) - Jan 15, 2016
P1, N=3, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=35 --> 3 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2015; Principal Investigator left the institution
- |||| recanaclotide (IW-9179) / Ironwood Pharma
Trial completion: Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) (clinicaltrials.gov) - Jan 7, 2016
P2, N=90, Completed, Sponsor: Ironwood Pharmaceuticals, Inc.
N=35 --> 3 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2015; Principal Investigator left the institution Recruiting --> Completed
- ||||||| onartuzumab (RG3638) / Roche
Trial completion, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Jan 4, 2016
P3, N=564, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Novel Esophago-Jejunal Anastomosis Method During Totally Laparoscopic Total Gastrectomy (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=10, Completed, Sponsor: Keimyung University Dongsan Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2015
- |||| camicinal (GSK962040) / GSK
Trial completion: A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis (clinicaltrials.gov) - Dec 21, 2015
P2, N=114, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2015 Recruiting --> Completed
- |||| MM 111 / Elevation Oncology
Trial completion, Metastases: A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach (clinicaltrials.gov) - Dec 16, 2015
P2, N=120, Completed, Sponsor: Merrimack Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Combination therapy: Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. (clinicaltrials.gov) - Dec 15, 2015
P1, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Mar 2016
- || velusetrag (TD-5108) / Innoviva
Trial primary completion date: The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study (clinicaltrials.gov) - Dec 14, 2015
P2, N=200, Recruiting, Sponsor: Theravance Biopharma R & D, Inc.
Trial primary completion date: Nov 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> May 2017
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial primary completion date: Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis (clinicaltrials.gov) - Dec 9, 2015
P1, N=18, Recruiting, Sponsor: The University of Hong Kong
Trial primary completion date: Dec 2015 --> May 2017 Trial primary completion date: Jan 2016 --> Sep 2016
- cabazitaxel / Generic mfg.
Enrollment closed, Metastases: Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Dec 5, 2015
P2, N=65, Active, not recruiting, Sponsor: Prof. Dr. S.E. Al-Batran
Trial primary completion date: Jan 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- pemetrexed / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2015
P1, N=33, Completed, Sponsor: University of Arizona
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche
Enrollment closed, Metastases: GATSBY: A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer (clinicaltrials.gov) - Dec 4, 2015
P3, N=415, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- ||| Trial completion: A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=32279, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion, Trial primary completion date: Rifaximin for Functional Dyspepsia (clinicaltrials.gov) - Dec 4, 2015
P2/3, N=95, Completed, Sponsor: The University of Hong Kong
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015
- oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer. (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=242, Completed, Sponsor: Tianshu Liu
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015 N=174 --> 242 | Trial primary completion date: Dec 2013 --> May 2015
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Trial primary completion date, Metastases: SOPP: S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer (clinicaltrials.gov) - Nov 30, 2015
P3, N=338, Completed, Sponsor: Min-Hee Ryu
N=174 --> 242 | Trial primary completion date: Dec 2013 --> May 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Oct 2014
- | dovitinib (TKI258) / Novartis, Oncoheroes
Trial completion, Enrollment change, Trial primary completion date, Metastases: Dovitinib Plus Docetaxel in Gastric Cancer (clinicaltrials.gov) - Nov 30, 2015
P1/2, N=14, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Oct 2014 Recruiting --> Completed | N=59 --> 14 | Trial primary completion date: Feb 2016 --> Aug 2015
- oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Enrollment closed: Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis (clinicaltrials.gov) - Nov 21, 2015
P2, N=32, Active, not recruiting, Sponsor: Samsung Medical Center
Recruiting --> Completed | N=59 --> 14 | Trial primary completion date: Feb 2016 --> Aug 2015 Recruiting --> Active, not recruiting
- || Trial primary completion date: HALT: Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding (clinicaltrials.gov) - Nov 16, 2015
P=N/A, N=80, Recruiting, Sponsor: Cook
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2014 --> Mar 2017
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Surgery: Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery (clinicaltrials.gov) - Nov 16, 2015
P2, N=0, Completed, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Mar 2014 --> Mar 2017 No longer recruiting --> Completed
- | Trial completion, Trial primary completion date: The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using Single-site for Surgical Treatment of Early Gastric Cancer (clinicaltrials.gov) - Nov 16, 2015
P1/2, N=19, Completed, Sponsor: Yonsei University
No longer recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Nov 2015
- || camicinal (GSK962040) / GSK
Trial primary completion date: Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study (clinicaltrials.gov) - Nov 15, 2015
P2, N=150, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Nov 2015 Trial primary completion date: Sep 2015 --> Aug 2016
- sirolimus / Generic mfg.
Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Nov 15, 2015
P1, N=30, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Sep 2015 --> Aug 2016 N=18 --> 30
- Trial completion, Trial primary completion date: Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=2024, Completed, Sponsor: Odense University Hospital
N=18 --> 30 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> May 2014
- Trial primary completion date: 124I-FIAU Imaging in EBV and KSHV Associated Cancers (clinicaltrials.gov) - Nov 10, 2015
P0, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> May 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche
Trial primary completion date, Metastases: GATSBY: A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer (clinicaltrials.gov) - Nov 10, 2015
P3, N=412, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2016 --> Mar 2016
- Trial completion: Transcutaneous Electroacupuncture for Gastroparesis (clinicaltrials.gov) - Nov 10, 2015
P1, N=26, Completed, Sponsor: Transtimulation Research, Inc
Trial primary completion date: Dec 2016 --> Mar 2016 Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date: Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes (clinicaltrials.gov) - Oct 29, 2015
P2, N=20, Recruiting, Sponsor: Royal Adelaide Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Jul 2015 | Trial primary completion date: Dec 2015 --> Aug 2016
- irinotecan / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 27, 2015
P2, N=40, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Jul 2015 | Trial primary completion date: Dec 2015 --> Aug 2016 Trial primary completion date: Jan 2015 --> Jun 2016
- |||| Bekinda (ondansetron controlled-release) / RedHill
Trial primary completion date: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Oct 22, 2015
P3, N=320, Recruiting, Sponsor: RedHill Biopharma Limited
Trial primary completion date: Jan 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- cabazitaxel / Generic mfg.
Trial primary completion date, Metastases: Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=65, Recruiting, Sponsor: Prof. Dr. S.E. Al-Batran
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Vectibix (panitumumab) / Amgen
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=51, Terminated, Sponsor: Hellenic Oncology Research Group
Trial primary completion date: Dec 2015 --> Mar 2016 N=108 --> 51 | Recruiting --> Terminated | Trial primary completion date: Jul 2014 --> Jan 2015; Not reached the primary endpoint target according to the statistical design
- esomeprazole / Generic mfg.
Trial completion, Enrollment change: The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers (clinicaltrials.gov) - Oct 14, 2015
P4, N=474, Completed, Sponsor: National Cheng-Kung University Hospital
N=108 --> 51 | Recruiting --> Terminated | Trial primary completion date: Jul 2014 --> Jan 2015; Not reached the primary endpoint target according to the statistical design Recruiting --> Completed | N=300 --> 474